SEARCH

SEARCH BY CITATION

References

  • 1
    Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975982.
  • 2
    Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958965.
  • 3
    Hadziyannis SJ, Sette Jr H, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140(5): 346355.
  • 4
    Consensus Development Panel. National institutes of health consensus development conference statement. Hepatology 2002; 36 (Suppl. 1): 5370.
  • 5
    Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39(4): 11471171.
  • 6
    Farrell GC. New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22(5): 607610.
  • 7
    Pegasys product label, Roche 2005Available at: http://www.rocheusa.com/products/pegasys/pi.pdf
  • 8
    PEG-Intron product label, Schering-Plough 2005Available at: http://www.spfiles.com/pipeg-intron.pdf
  • 9
    Shiffman ML, Suter F, Bacon BR et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357(2): 124134.
  • 10
    Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol 2006; 62(6): 699709.
  • 11
    Willems B, Hadziyannis SJ, Morgan TR et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virological response? J Hepatol 2007; 46(Suppl 1): S6.
  • 12
    Zeuzem S. Standard treatment of acute and chronic hepatitis C. Z Gastroenterol 2004; 42(8): 714719.
  • 13
    Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am J Gastroenterol 2006; 101(10): 23602378.
    Direct Link:
  • 14
    Shiffman ML, Ferreira-Gonzalez A, Reddy KR et al. Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice. Am J Gastroenterol 2003; 98: 11591166.
    Direct Link:
  • 15
    Sarrazin C, Shiffman ML, Hadziyannis SJ et al. What is the impact of higher sensitivity assay on response-guided therapy in hepatitis C virus (HCV)? Comparative analysis between TAQMAN and AMPLICOR tests from two large randomised international trials of Pegasys plus Copegus.. Hepatology 2007; 46(4 Suppl 1): 813A.
  • 16
    Sarrazin C, Gärtner BC, Sizmann D et al. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol 2006; 44(3): 729737.
  • 17
    Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007; 46(1): 2231.
  • 18
    Michelin BD, Muller Z, Stelzl E, Marth E, Kessler HH. Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA. J Clin Virol 2007; 38(2): 96100.
  • 19
    Halfon PG, Penaranda M, Bourliere H et al. Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection. J Med Virol 2006; 78: 208215.
  • 20
    Chevaliez S, Pawlotsky JM. Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. Int J Med Sci 2006; 3(2): 3540.
  • 21
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38(3): 645652.
  • 22
    Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43(3): 425433.
  • 23
    Russo MW, Fried MW. Guidelines for stopping therapy in chronic hepatitis C. Curr Gastroenterol Rep 2004; 6(1): 1721.
  • 24
    Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37(3): 600609.
  • 25
    Afdhal N, Freilich B, Levine R et al. Colchicine versus Peg-Intron Long Term (COPILOT) trial: Interim analysis of clinical outcomes at year 2. Hepatology 2004; 40: 238A.
  • 26
    Afdhal NH, Levine R, Brown R, Freillich B, O’Brien M, Brass C. Colehicine versus peg-interferon alfa 2b long term therapy: results of the 4 year COPILOT trial. J Hepatol 2008; 48 (Suppl. 2): S4.
  • 27
    Poynard T, Schiff E, Terg R et al. Sustained virologic response (SVR) in the EPIC(3) trial: week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving Pegintron/Rebetol (PR) weight based dosing (WBD). J Hepatol 2005; 42(Suppl 2): 4041.
  • 28
    Di Bisceglie A, Shiffman ML, Everson GT et al. Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2007; 46(Suppl. 1): 290A.
  • 29
    Shiffman ML, Morishima C, Lindsay KL et al. Suppression of serum HCV RNS levels during maintenance peginterferon (PEGIFN) alfa-2a therapy and clinical outcomes in the HALT-C trial. J Hepatol 2008; 48 (Suppl. 2): 144A.
  • 30
    Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44(1): 97103.
  • 31
    Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43(5): 954960.
  • 32
    Zeuzem S, Diago M, Gane E et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127(6): 17241732.
  • 33
    Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352(9138): 14261432.
  • 34
    McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339(21): 14851492.
  • 35
    Pawlotsky JM, Bouvier-Alias M, Hezode C et al. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32(3): 654659.
  • 36
    Berg T, Von Wagner M, Hinrichsen H et al. Definition of a pre-treatment viral load cutoff for an optimized prediction of treatment outcome in patients with genotype 1 infection receiving either 48 or 72 weeks of peginterferon alfa-2a plus ribavirin. Hepatololgy 2006; 44(Suppl 1): 321A.
  • 37
    Zeuzem S, Fried MW, Reddy KR et al. Improving the clinical relevance of pretreatment viral load as a predictor of sustained virological response (SVR) in patients infected with hepatitis C genotype 1 treated with peginterferon alfa-2a (40kd) (PEGASYS®) plus ribavirin (COPEGUS). Hepatology 2006; 44(Suppl 1): 267A.
  • 38
    Zehnter E, Mauss S, John C et al. Better prediction of SVR in patients with HCV genotype 1 (G1) with peginterferon alfa-2a (PEGASYS) plus ribavirin: improving differentiation between low (LVL) and high baseline viral load (HVL). Hepatology 2006; 44(4 Suppl 1): 328A.
  • 39
    Martinot-Peignoux M, Ripault MP, Maylin S et al. Optimal pre-treatment viral load cut-off to predict treatment outcome in patients with chronic hepatitis C treated with peginterferon alfa-2b plus ribavirin. J Hepatol 2007; 46(Suppl 1): S234.
  • 40
    Ghalib RH, Levine C, Steephen A, Mubarak A, Weinstein J. Factors impacting SVR in HCV genotype 1 patients with EVR and week 24 negativity. Hepatology 2007; 46(Suppl 1): 391A.
  • 41
    Sulkowski M, Lawitz E, Shiffman ML et al. Final results of the IDEAL (individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) Phase IIIB study. J Hepatol 2008; 48 (Suppl. 2): S370S371. Late-breaker abstract.
  • 42
    Lindahl K, Stahle L, Bruchfeld A, Schwarcz R. High-dose ribavirin in combination with standard dose peginterfern for treatment of patients with chronic hepatitis C. Hepatology 2005; 41: 275279.
  • 43
    Fried M, Jensen D, Rodriguez-Torres M et al. Improved sustained virological response (SVR) rates with higher, fixed doses of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (RBV)(COPEGUS®) in patients with ‘difficult-to-cure’ characteristics. Hepatology 2006; 44(Suppl 1): 314A.
  • 44
    Shiffman ML, Salvatore J, Hubbard S et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46(2): 371379.
  • 45
    Berg T, Von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130(4): 10861097.
  • 46
    Sanchez-Tapias JM, Diago M, Escartin P et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131(2): 451460.
  • 47
    Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007; 46(6): 16881694.
  • 48
    Sanchez-Tapias JM, Ferenci P, Diago M, Romero-Gomez M, Zeuzem S, Berg T. How can we identify HCV genotype 1 patients who may benefit from an extended treatment duration with peginterferon alfa-2a (40 kd) plus RBV? J Hepatol 2007; 46(Suppl 1): S243.
  • 49
    Mangia A, Santoro R, Minerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 26092617.
  • 50
    Von Wagner M, Huber M, Berg T et al. Peginterferon-alpha-2a (40 KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522527.
  • 51
    Andriulli A, Dalgard O, Bjøro K, Mangia A. Short-term treatment duration for HCV-2 and HCV-3 infected patients. Dig Liver Dis 2006; 38(10): 741748.
  • 52
    Yu ML, Dai CY, Huang JF et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553559.
  • 53
    Dalgard O, Bjoro K, Hellum KB et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 12601265.
  • 54
    Dalgard O, Bjøro K, Ring-Larsen H et al. Pegylated interferon alfa-2b and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47(1): 3542.
  • 55
    Zeuzem S, Pawlotsky JM, Lukasiewicz E et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43(2): 250257.
  • 56
    Brown R, Jacobson I, Afdhal N et al. Risk factors for relapse in genotype 3 high viral load patients with hepatitis C in the WIN-R trial. Hepatology 2006; 44(Suppl 1): 609A610A.
  • 57
    Aghemo A, Rumi MG, Soffredini R et al. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antivir Ther 2006; 11(6): 797802.
  • 58
    Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci 2006; 8: 832842.
  • 59
    Ferenci P, Brunner H, Laferl H et al. Further reduction of ribavirin dose in HCV genotype 2/3 patients receiving peginterferon alfa-2a (40 kd) (PEGASYS®) plus ribavirin (COPEGUS®): interim results of a randomised controlled trial. J Hepatol 2006; 44(Suppl 2): S37.
  • 60
    Dieterich DT, Wasserman R, Bräu N et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98(11): 24912499.
  • 61
    Afdhal NH, Dieterich DT, Pockros PJ et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126(5): 13021311.
  • 62
    Pockros PJ, Shiffman ML, Schiff ER et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004; 40(6): 14501458.
  • 63
    Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004; 11(1): 8487.
  • 64
    McHutchison JG, Manns MP, Brown Jr RS, Reddy KR, Shiffman ML, Wong JB. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007; 102(4): 880889.
    Direct Link:
  • 65
    Ferenci P, Brunner H, Laferl H et al. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 2008; 47: 18161823.
  • 66
    McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123(4): 10611069.
  • 67
    Shiffman ML, Di Bisceglie AM, Lindsay KL et al. Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126(4): 10151023.
  • 68
    Ferenci P, Brunner H, Nachbaur K et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001; 34(5): 10061011.
  • 69
    Mulhall BP, Younossi Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 2005; 39(1 Suppl): S23S27.
  • 70
    Reddy KR, Shiffman ML, Morgan TR et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5(1): 124129.
  • 71
    Parise E, Cheinquer H, Crespo D et al. Peginterferon alfa-2a (40 KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy. Braz J Infect Dis 2006; 10(1): 11.
  • 72
    Sherman M, Yoshida EM, Deschenes M et al. Peginterferon alfa-2a (40 KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006; 55(11): 16311638.
  • 73
    Mathew A, Peiffer LP, Rhoades K, McGarrity T. Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment. Dig Dis Sci 2006; 51(11): 19561961.
  • 74
    Basso M, Torre F, Blanchi S, Delfino A, Picciotto A. Long-term virological follow-up of patients with chronic hepatitis C who obtained a sustained virological response after treatment with pegylated interferon and ribavirin. J Hepatol 2007; 46(Suppl 1): S201.
  • 75
    Sagir A, Heintges T, Akyazi Z, Oette M, Erhardt A, Häussinger D. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection. Liver Int 2007; 27(7): 954959.
  • 76
    Moucari R, Ripault MP, Oulès V et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol 2007; 46(4): 596604.
  • 77
    Poynard T, Schiff E, Terg R, Moreno-Otero R, Flamm S et al. Platelet count predicts sustained viral response (SVR) in the re-treatment of previous interferon/ribavirin non-responders (NR): Results from the EPIC3 program. J Hepatol 2008; 48 (Suppl 2): 822A.
  • 78
    Cecil BD, Lavelle M. Sustained viral response improves survival in patients with either compensated or decompensated hepatitis C. J Hepatol 2005; 42(Suppl 2): A21.
  • 79
    Cammà C, Giunta M, Chemello L et al. Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. Hepatology 1999; 30(3): 801807.
  • 80
    Cummings KJ, Lee SM, West ES et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. J Am Med Assoc 2001; 285(2): 193139.
  • 81
    Poynard T, Schiff E, Terg R et al. HCV RNA negativity after 12 weeks of therapy is the best predictor of sustained virological response (SVR) in the re-treatment of previous interferon alfa/ribavirin non-responders (NR): results from the EPIC3 program. Hepatology 2006; 44: 606A.
  • 82
    Jensen DM, Freilich B, Andreones P et al. Pegylated interferon alfa-2a (40 KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12 KD)/RBV: final efficacy and safety outcomes of the REPEAT study. Hepatology 2007; 46(4 Suppl): 80A.
  • 83
    Kaiser S, Lutze B, Sauter B et al. Long-term low dose treatment with pegylated interferon alpha 2b leads to a significant reduction in fibrosis and inflammatory score in chronic hepatitis C nonresponder patients with fibrosis or cirrhosis. Hepatology 2007; 46(4 Suppl): 820A.